Abstract
ObjectivesWomen with recurrent endometrial cancer who fail carboplatin and paclitaxel have a poor prognosis with few effective options. The recent GARNET Trial showed promising results for dostarlimab in these patients....
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have